Potential for molecular targeted therapy of HER-2/neu for invasive bladder cancer: Examination of gene amplification by fluorescence in situ hybridization

Yoshiaki Yamada, Katsuya Naruse, Kogenta Nakamura, Shigeyuki Aoki, Tomohiro Taki, Motoi Tobiume, Kenji Zennami, Remi Katsuda, Miki Hirano, Keiko Hayashida, Emi Mizumukai, Hiroshi Nanaura, Nobuaki Honda

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Analysis of HER-2/neu gene amplification by fluorescence in situ hybridization was performed in 40 patients with invasive bladder cancer in order to evaluate the potential for molecular targeted therapy of HER-2 as a tailor-made treatment for patients with invasive bladder cancer. This study included 40 patients seen at the Aichi Medical University Hospital from January 2001 to December 2004 and were pathologically diagnosed with invasive transitional cell carcinoma of the bladder (pT2-pT4). The PathVysion kit was used to evaluate the status of HER-2/neu gene amplification, and a signal ratio ≥2.0 was considered positive for HER-2/neu gene amplification. In primary foci 5 patients (12.5%) were positive for HER-2/neu gene amplification. According to the classification of grade and stage, no statistically significant difference was observed. Lymph node metastasis was found in 10 patients, and 3 patients (30%) were positive for HER-2/neu gene amplification. In the patients with HER-2/neu gene-amplified metastatic lymph nodes, primary foci were also positive for gene amplification, showing a statistically significant difference. This study indicates that 12.5% of patients with invasive bladder cancer may benefit from molecular targeted therapy of HER-2, and that molecular targeted therapy can be expected to be effective even for patients with lymph node metastases as long as their primary foci are positive for HER-2/neu gene amplification.

Original languageEnglish
Pages (from-to)1183-1187
Number of pages5
JournalOncology reports
Volume18
Issue number5
Publication statusPublished - 01-11-2007
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Potential for molecular targeted therapy of HER-2/neu for invasive bladder cancer: Examination of gene amplification by fluorescence in situ hybridization'. Together they form a unique fingerprint.

  • Cite this

    Yamada, Y., Naruse, K., Nakamura, K., Aoki, S., Taki, T., Tobiume, M., Zennami, K., Katsuda, R., Hirano, M., Hayashida, K., Mizumukai, E., Nanaura, H., & Honda, N. (2007). Potential for molecular targeted therapy of HER-2/neu for invasive bladder cancer: Examination of gene amplification by fluorescence in situ hybridization. Oncology reports, 18(5), 1183-1187.